PMID- 31663373
OWN - NLM
STAT- MEDLINE
DCOM- 20200605
LR  - 20200605
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 79
IP  - 8
DP  - 2019 Dec
TI  - Clinicopathological and prognostic values of ErbB receptor family amplification 
      in primary osteosarcoma.
PG  - 601-612
LID - 10.1080/00365513.2019.1683764 [doi]
AB  - Osteosarcoma is a malignant bone tumor with extremely high invasion, metastasis 
      and mortality. The prognosis of patients with osteosarcoma remains poor. The ErbB 
      receptor family was found to be overexpressed in human cancers and associated 
      with poor prognosis. However, the role of ErbB receptor family in osteosarcoma 
      has not been fully understood. The present study aimed to investigate the 
      clinicopathological and prognostic significances of ErbB receptors in primary 
      osteosarcoma. Western blot (WB), reverse transcription-quantitative polymerase 
      chain reaction (RT-qPCR) and fluorescence in situ hybridization (FISH) were used 
      to detect the protein and gene expression of ErbB receptors in 60 primary 
      osteosarcoma specimens and 30 non-neoplastic bone tissues. WB and RT-qPCR 
      analyses showed that the protein and mRNA expression levels of EGFR, ErbB3 and 
      ErbB4 in osteosarcoma specimens were significantly higher than those in 
      non-neoplastic bone tissues. Seventeen (28.33%), 15 (25.00%) and 15 (25.00%) 
      osteosarcoma specimens presented with amplification of EGFR, ErbB3 and ErbB4 
      gene, respectively, which were significantly higher compared with non-neoplastic 
      bone tissues. The amplification of ErbB3 and ErbB4 in osteosarcoma was associated 
      with advanced surgical stage. The amplification of EGFR, ErbB3, ErbB4 and the 
      co-amplification of EGFR-ErbB3, EGFR-ErbB4, ErbB3-ErbB4 was linked with poor 
      response to chemotherapy and distant metastasis. The amplification of EGFR, ErbB3 
      and ErbB4, as well as their co-amplification demonstrated independent prognostic 
      values for reduced survival time of osteosarcoma patients and may serve as 
      potential therapeutic targets for osteosarcoma patients in the future.
FAU - Huang, Zhen
AU  - Huang Z
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Wang, Sheng-Lin
AU  - Wang SL
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Nephrology, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Shen, Rong-Kai
AU  - Shen RK
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Li, Xiao-Dong
AU  - Li XD
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Huang, Qing-Shan
AU  - Huang QS
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Wu, Chao-Yang
AU  - Wu CY
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Weng, Dan-Feng
AU  - Weng DF
AD  - Department of Pathology, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
FAU - Lin, Jian-Hua
AU  - Lin JH
AD  - Department of Orthopedics, the First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, P.R. China.
AD  - Fujian Provincial Institute of Orthopedics, the First Affiliated Hospital of 
      Fujian Medical University, Fuzhou, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20191030
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone and Bones/metabolism/pathology
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Osteosarcoma/*genetics/*pathology
MH  - Prognosis
MH  - RNA, Messenger/genetics/metabolism
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - ErbB family
OT  - Osteosarcoma
OT  - amplification
OT  - prognosis
OT  - survival
EDAT- 2019/10/31 06:00
MHDA- 2020/06/06 06:00
CRDT- 2019/10/31 06:00
PHST- 2019/10/31 06:00 [pubmed]
PHST- 2020/06/06 06:00 [medline]
PHST- 2019/10/31 06:00 [entrez]
AID - 10.1080/00365513.2019.1683764 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2019 Dec;79(8):601-612. doi: 
      10.1080/00365513.2019.1683764. Epub 2019 Oct 30.